Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RYZB

RayzeBio (RYZB) Stock Price, News & Analysis

RayzeBio logo

About RayzeBio Stock (NASDAQ:RYZB)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$62.49
$62.49
50-Day Range
$62.27
$62.49
52-Week Range
$17.95
$62.51
Volume
N/A
Average Volume
553,592 shs
Market Capitalization
$3.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Remove Ads
Receive RYZB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RayzeBio and its competitors with MarketBeat's FREE daily newsletter.

RYZB Stock News Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
Getting In on This "Macro-Trend"
Andreas Halvorsen's Firm Sells Out of RayzeBio Inc
RYZB Aug 2024 35.000 put
RYZB May 2024 55.000 put
See More Headlines

RYZB Stock Analysis - Frequently Asked Questions

RayzeBio (RYZB) raised $311 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 17,277,600 shares at a price of $18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that RayzeBio investors own include Apogee Therapeutics (APGE), Broadcom (AVGO), Citigroup (C), Citizens Financial Group (CFG), Cisco Systems (CSCO), Fifth Third Bancorp (FITB) and Intel (INTC).

Company Calendar

Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RYZB
Fax
N/A
Employees
88
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.74 billion
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:RYZB) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners